Peloton Therapeutics Appoints Timothy P. Coughlin and Thilo Schroeder, Ph.D. to its Board of Directors
DALLAS--(BUSINESS WIRE)--May 7, 2019--Peloton Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing first-in-class oral medicines for cancer and other serious conditions, announced that Timothy P. Coughlin, former Chief Financial Officer of Neurocrine Biosciences, Inc., and Thilo Schroeder, Ph.D., Partner at Nextech Invest, Ltd. and former Peloton Board Observer, have been appointed to its Board of Directors. Steve Winick, J.D., Managing Director of Topspin Partners, who has been a director since 2016, has resigned from the Board.
“We thank Steve for his diligent service and are pleased to welcome these two distinguished leaders to our Board of Directors,” said John A. Josey, Ph.D., Peloton’s Chief Executive Officer. “Tim has been instrumental to the success of a high-growth clinical-stage organization and its transition to a commercial-stage company with successful FDA approvals in recent years. He brings substantive executive management experience in financial functions as well as healthcare expertise. Thilo, who has a deep understanding of our company and programs from his years as a Board Observer, brings considerable scientific and business acumen as an oncology company investor.”
Timothy P. Coughlin was with Neurocrine Biosciences, Inc. from 2002 to 2018 and began serving as their Chief Financial Officer in 2006. Prior to joining Neurocrine, Mr. Coughlin served as Vice President, Financial Services at Catholic Health Initiatives, a nationwide integrated healthcare delivery system. From 1989 to 1999, Mr. Coughlin was a Senior Manager in the Health Sciences practice of Ernst & Young LLP and its predecessors. He currently serves on the Board of Directors of Fate Therapeutics, aTyr Pharma and Retrophin. Mr. Coughlin holds a master’s degree in international business from San Diego State University and a bachelor’s degree in accounting from Temple University. Mr. Coughlin is a certified public accountant in both California and Pennsylvania.
Thilo Schroeder, Ph.D. is a Partner at Nextech Invest Ltd., a global venture fund focused on investing in leading oncology companies. He joined Nextech Invest in 2012. Dr. Schroeder currently serves as board member of Revolution Medicines, IDEAYA Bioscience and ImaginAb, and observer of Black Diamond Therapeutics. He is a prior board member of Blueprint Medicines and board observer of Tracon Pharmaceuticals. He holds a Ph.D. in biochemistry from the University of Zurich in Switzerland, a M.Sc. in biotechnology from the Ecole de Supérieure de Biotechnologie de Strasbourg in France, and a B.Sc. in biology from the Technical University of Darmstadt in Germany.
About Peloton Therapeutics
Peloton Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on translating novel scientific insights into first-in-class medicines for patients with cancer and other debilitating or life-threatening conditions. The company’s lead development program is evaluating a small-molecule inhibitor of hypoxia-inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of clear cell renal cell carcinoma and a variety of other disorders. HIF-2α was previously thought to be intractable using small molecules. To learn more about Peloton Therapeutics, visit http://www.pelotontherapeutics.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190507005195/en/
CONTACT: Alan Musso
Chief Financial Officer
Phone: +1 (972) 629-4070
Sam Brown Inc.
Phone: +1 (312) 961-2502
KEYWORD: UNITED STATES NORTH AMERICA TEXAS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE
SOURCE: Peloton Therapeutics, Inc.
Copyright Business Wire 2019.
PUB: 05/07/2019 08:00 AM/DISC: 05/07/2019 08:01 AM